Pharmacological and Endoscopic Interventions for Prophylaxis of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

被引:0
|
作者
Palomera-Tejeda, Emmanuel [1 ]
Shah, Mihir Prakash [1 ]
Attar, Bashar M. [2 ,3 ]
Shah, Hassam [2 ]
Sharma, Bharosa [1 ]
Oleas, Roberto [1 ]
Kotwal, Vikram [2 ,3 ]
Gandhi, Seema [2 ]
Mutneja, Hemant Raj [2 ,3 ]
机构
[1] John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL 60612 USA
[2] John H Stroger Jr Hosp Cook Cty, Div Gastroenterol & Hepatol, Chicago, IL 60612 USA
[3] Rush Univ, Div Gastroenterol & Hepatol, Med Ctr, Chicago, IL USA
关键词
Endoscopic retrograde cholangiopancreatography; Post-ERCP pancreatitis; Rectal NSAIDs; Pancreatic duct stenting; Chronic statin use; Chronic aspirin use; Retrospective cohort study; ERCP PANCREATITIS; RISK-FACTORS; PREVENTION; COMPLICATIONS; INDOMETHACIN; METAANALYSIS; STATINS;
D O I
10.14740/gr1620
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Post-endoscopic retrograde cholangiopancreatogra-phy pancreatitis (PEP) represents the most common serious com-plication after endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal anti-inflammatory drugs (NSAIDs) and pancreatic duct stenting (PDS) are the prophylactic interven-tions with more evidence and efficacy; however, PEP still represents a significant source of morbidity, mortality, and economic burden. Chronic statin use has been proposed as a prophylactic method that could be cheap and relatively safe. However, the evidence is conflict-ing. We aimed to evaluate the impact of endoscopic and pharmaco-logical interventions including chronic statin and aspirin use, on the development of PEP.Methods: A retrospective cohort study evaluated consecutive patients undergoing ERCP at John H. Stroger, Jr. Hospital of Cook County in Chicago from January 2015 to March 2018. Univariate and multivari-ate analyses were performed using logistic regression.Results: A total of 681 ERCPs were included in the study. Twelve (1.76%) developed PEP. Univariate, multivariate, and subgroup anal-yses did not show any association between chronic statin or aspirin use and PEP. PDS and rectal indomethacin were protective in patients undergoing pancreatic duct injection. Pancreatic duct injection, fe-male sex, and younger age were associated with a higher risk. History of papillotomy was associated with lower risk only in the univariate analysis (all P values < 0.05).Conclusion: Chronic use of statins and aspirin appears to add no ad-ditional benefit to prevent ERCP pancreatitis. Rectal NSAIDs, and PDS after appropriate patient selection continue to be the main pro-phylactic measures. The lower incidence at our center compared with the reported data can be explained by the high rates of rectal indo-methacin and PDS, the use of noninvasive diagnostic modalities for patient selection, and the expertise of the endoscopists.
引用
收藏
页码:149 / 156
页数:8
相关论文
共 50 条
  • [31] Is post-endoscopic retrograde cholangiopancreatography pancreatitis the same as acute clinical pancreatitis?
    Mine, Tetsuya
    JOURNAL OF GASTROENTEROLOGY, 2007, 42 (03) : 265 - 266
  • [32] No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Hirotoshi Ishiwatari
    Takahiro Urata
    Ichiro Yasuda
    Shimpei Matsusaki
    Hiroyuki Hisai
    Hiroshi Kawakami
    Michihiro Ono
    Takuji Iwashita
    Shinpei Doi
    Kazumichi Kawakubo
    Tsuyoshi Hayashi
    Tomoko Sonoda
    Naoya Sakamoto
    Junji Kato
    Digestive Diseases and Sciences, 2016, 61 : 3292 - 3301
  • [33] Pancreatic Stents for prevention of post-endoscopic retrograde Cholangiopancreatography pancreatitis
    Freeman, Martin L.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (11) : 1354 - 1365
  • [34] Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis
    Khoshbaten, Manouchehr
    Khorram, Homayoun
    Madad, Leili
    Ardakani, Mohammad Javad Ehsani
    Farzin, Haleh
    Zali, Mohammmad Reza
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (07) : E11 - E16
  • [35] preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta analysis
    Dan, Jiang
    Yu, Laiming
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 888 - 888
  • [36] Best practices for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Weissman, Simcha
    Ahmed, Mohamed
    Baniqued, Matthew R.
    Ehrlich, Dean
    Tabibian, James H.
    WORLD JOURNAL OF GASTROINTESTINAL ENDOSCOPY, 2021, 13 (06): : 161 - 169
  • [37] Race as a Risk Factor for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Rogers, Hayley K.
    Haddad, James
    Liu, Po-Hong
    Chang, Patrick
    Phan, Jennifer
    Tielleman, Thomas
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1143 - S1143
  • [38] Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Medications and Techniques
    Wang, Andrew Y.
    Strand, Daniel S.
    Shami, Vanessa M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (11) : 1521 - +
  • [39] Indomethacin to Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: When and How?
    George, John
    Saluja, Ashok K.
    Barkin, Jamie S.
    GASTROENTEROLOGY, 2017, 152 (01) : 306 - 307
  • [40] No Benefit of Oral Diclofenac on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Ishiwatari, Hirotoshi
    Urata, Takahiro
    Yasuda, Ichiro
    Matsusaki, Shimpei
    Hisai, Hiroyuki
    Kawakami, Hiroshi
    Ono, Michihiro
    Iwashita, Takuji
    Doi, Shinpei
    Kawakubo, Kazumichi
    Hayashi, Tsuyoshi
    Sonoda, Tomoko
    Sakamoto, Naoya
    Kato, Junji
    DIGESTIVE DISEASES AND SCIENCES, 2016, 61 (11) : 3292 - 3301